Biosimilars for IBD, including Crohn’s disease and ulcerative colitis, are entering the U.S. market.

An interchangeable biosimilar means the drug could be automatically switched between the reference product and the biosimilar through the pharmacy. So far, there are no approved interchangeable biosimilars yet.

The effects of switching from the reference drug to a biosimilar are being studied.

Memorize the name of the biologic you are currently taking.

It’s up to you to SPEAK UP.

Discuss preferences to stay on the reference drug or switch to a biosimilar with your doctor.

Tell your pharmacist your preference and review the label of the medicine package you receive.

You have the right to take your preferred medication — the decision is between you and your doctor.

You have the right to appeal a switch to a biosimilar with your insurance company. Your doctor can help!

Advocate for Your Patient Rights at the PHARMACY & DOCTOR’S OFFICE